Question 1

What is Eli Lilly's P/E ratio?

Accepted Answer

Eli Lilly (LLY) P/E ratio is 41.2× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month earnings (net income), using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for Eli Lilly?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For Eli Lilly specifically, the relevant sector benchmark is the current sector median of 24.2×.

Question 5

Is Eli Lilly's P/E ratio high or low?

Accepted Answer

Eli Lilly's P/E ratio of 41.2× is below its own 5-year average of 63.2× and above the sector median of 24.2×. That places the current reading at the 15th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Eli Lilly's historical P/E ratio range?

Accepted Answer

In the available daily series, Eli Lilly (LLY) P/E ratio has ranged from a low of 7.7× in 2010 to a high of 243.9× in 2018. The 5-year average is 63.2× and the 5-year median is 53.5×.

Question 7

What was Eli Lilly's P/E ratio in 2025?

Accepted Answer

Eli Lilly (LLY) P/E ratio at the end of 2025 was 46.8×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month earnings figure available at that date.

Question 8

Why does Eli Lilly's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$965B	$20.6B	46.8×	-18.7×	Dec 31, 2025
2024	$693B	$10.6B	65.4×	-34.6×	Dec 31, 2024
2023	$524B	$5.24B	100.0×	+44.4×	Dec 31, 2023
2022	$348B	$6.24B	55.7×	+8.5×	Dec 31, 2022
2021	$263B	$5.58B	47.2×	+21.1×	Dec 31, 2021
2020	$162B	$6.19B	26.1×	+10.9×	Dec 31, 2020
2019	$126B	$8.32B	15.1×	-21.7×	Dec 31, 2019
2018	$119B	$3.23B	36.8×	—	Dec 31, 2018
2017	$88.9B	-$204M	—	—	Dec 31, 2017
2016	$81B	$2.74B	29.6×	-9.1×	Dec 31, 2016
2015	$93.1B	$2.41B	38.7×	+6.6×	Dec 31, 2015
2014	$76.6B	$2.39B	32.1×	+19.9×	Dec 31, 2014
2013	$57B	$4.68B	12.2×	-1.7×	Dec 31, 2013
2012	$56.5B	$4.09B	13.8×	+3.2×	Dec 31, 2012
2011	$46.4B	$4.35B	10.7×	+3.0×	Dec 31, 2011
2010	$38.9B	$5.07B	7.7×	-1.4×	Dec 31, 2010
2009	$39.2B	$4.33B	9.1×	—	Dec 31, 2009
2008	$44.1B	-$2.07B	—	—	Dec 31, 2008
2007	$58.2B	$2.95B	19.7×	-1.5×	Dec 31, 2007
2006	$56.5B	$2.66B	21.2×	-9.8×	Dec 31, 2006
2005	$61.5B	$1.98B	31.0×	-2.9×	Dec 31, 2005
2004	$61.4B	$1.81B	33.9×	+4.3×	Dec 31, 2004
2003	$75.9B	$2.56B	29.6×	+4.4×	Dec 31, 2003
2002	$68.3B	$2.71B	25.2×	—	Dec 31, 2002


Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Illumina (ILMN)	21.7×
ResMed (RMD)	21.6×
GE HealthCare (GEHC)	21.6×
Pfizer (PFE)	21.1×
Quest Diagnostics (DGX)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Gilead Sciences (GILD)	18.8×
Humana (HUM)	18.5×
Regeneron Pharmaceuticals (REGN)	18.2×
Bristol-Myers Squibb (BMY)	17.0×
Elevance Health (ELV)	17.0×
HCA Healthcare (HCA)	15.8×
AstraZeneca (AZN)	14.7×
DaVita (DVA)	13.3×
Incyte (INCY)	13.1×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for Eli Lilly (LLY) 2002-2026

P/E Ratio daily chart for Eli Lilly (LLY)

Historical P/E Ratio for Eli Lilly (LLY) from 2002 to 2025

About P/E Ratio at Eli Lilly (LLY)

Eli Lilly P/E Ratio by Year

Eli Lilly P/E Ratio 2025: 46.8×

Eli Lilly P/E Ratio 2024: 65.4×

Eli Lilly P/E Ratio 2023: 100.0×

Eli Lilly P/E Ratio 2022: 55.7×

Eli Lilly P/E Ratio 2021: 47.2×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

Eli Lilly (LLY) Key Financials